CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Ratings Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 199.06 USD | -0.27% |
|
+1.68% | -15.80% |
Summary: Charles River Laboratories International, Inc.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- According to Refinitiv, the company's ESG score for its industry is good.
Highlights: Charles River Laboratories International, Inc.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses: Charles River Laboratories International, Inc.
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.13 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings Chart: Charles River Laboratories International, Inc.
Source: Surperformance
ESG chart: Charles River Laboratories International, Inc.
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 10.18B | |||||
| 43.12B | |||||
| 36.45B | |||||
| 27.58B | |||||
| 17.36B | |||||
| - | 16.57B | ||||
| 16.54B | |||||
| 11.97B | |||||
| 10.56B | |||||
| Average | 21.15B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
C+
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CRL Stock
- Ratings Charles River Laboratories International, Inc.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition